In current studies, we further evaluated XBP1-CTL post-lenalidomide treatment for their specific anti-tumor activity by measuring IFN-γ production and granzyme B expression against the respective HLA-A2+ solid tumor cells. The gene discussed is IFNG; the disease is neoplasm.